[ | E-mail ] Contact: Ronald Rogersrrogers@myriad.com 801-584-3065Myriad Genetics, Inc. Myriad submits updated dossier for Medicare reimbursement SALT LAKE CITY, Utah, March 3, 2014 Myriad Genetics, Inc. (Nasdaq: MYGN) today announced that it has published data from the PROCEDE 500…
Source:Myriad publishes clinical utility study for Prolaris
Monday, March 3, 2014
Myriad publishes clinical utility study for Prolaris
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment